Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:XLRN

Acceleron Pharma (XLRN) Stock Price, News & Analysis

Acceleron Pharma logo

About Acceleron Pharma Stock (NASDAQ:XLRN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$178.75
$178.75
50-Day Range
$172.08
$179.68
52-Week Range
$108.82
$189.99
Volume
N/A
Average Volume
572,759 shs
Market Capitalization
$10.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Remove Ads
Receive XLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

XLRN Stock News Headlines

Acceleron Banks on Muons for Colder Fusion
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
See More Headlines

XLRN Stock Analysis - Frequently Asked Questions

Acceleron Pharma Inc. (NASDAQ:XLRN) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.18. The firm's revenue was up 51.6% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
11/04/2021
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:XLRN
Employees
312
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-166,030,000.00
Net Margins
-226.01%
Pretax Margin
-225.99%

Debt

Sales & Book Value

Annual Sales
$92.52 million
Price / Cash Flow
N/A
Book Value
$11.74 per share
Price / Book
15.23

Miscellaneous

Free Float
60,116,000
Market Cap
$10.93 billion
Optionable
Optionable
Beta
0.13

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:XLRN) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners